About: Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction
Creator	Chen, Jaw-Chyun Ho, Tin-Yun Hsiang, Chien-Yun Wu, Shih-Lu Chang, Yung-Hsien Cheng, Shin-Ei Liu, Hsu-Jan Wei, Yen-Chiao
Source	Elsevier; Medline; PMC
abstract	Abstract Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The binding of SARS-CoV spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) is the first step in SARS-CoV infection. Therefore, we assayed the inhibitory effects of small peptides derived from S protein on the binding of S protein to ACE2 and on the S-protein-pseudotyped retrovirus infectivity. SP-4 (residues 192–203), SP-8 (residues 483–494), and SP-10 (residues 668–679) significantly blocked the interaction between S protein and ACE2 by biotinylated enzyme-linked immunosorbent assay, with IC50 values of 4.30±2.18, 6.99±0.71, and 1.88±0.52nmol, respectively. Peptide scanning suggested the region spanning residues 660–683 might act as a receptor-binding domain. SP-10 blocked both binding of the S protein and infectivity of S protein-pseudotyped retrovirus to Vero E6 cells. In conclusion, this is the first report of small peptides designed to disrupt the binding of SARS-CoV S protein to ACE2. Our findings suggest that SP-10 may be developed as an anti-SARS-CoV agent for the treatment of SARS-CoV infection.
has issue date	2006-02-28(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2005.10.005
bibo:pmid	16337697
has license	els-covid
sha1sum (hex)	bd46c298f59ed56172a513e7f6be52362e98557f
schema:url	https://doi.org/10.1016/j.antiviral.2005.10.005
resource representing a document's title	Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction
has PubMed Central identifier	PMC7114127
has PubMed identifier	16337697
schema:publication	Antiviral Research
resource representing a document's body	covid:bd46c298f59ed56172a513e7f6be52362e98557f#body_text
is schema:about of	named entity 'ACE2' named entity 'angiotensin-converting enzyme 2' named entity 'blocked' named entity 'effects' named entity 'spanning' named entity 'residues' named entity 'interaction' named entity 'SARS-CoV' named entity 'BIOLOGICAL' named entity 'SARS-COV' named entity '1.88' named entity 'FIRST STEP' named entity 'ACT' named entity '192' named entity 'VERO' named entity 'NOVEL CORONAVIRUS' named entity 'EFFECTS' named entity 'BLOCKED' named entity 'FINDINGS' named entity '203' named entity 'SP-10' named entity 'RECEPTOR' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity '28S' named entity 'REGION' covid:arg/bd46c298f59ed56172a513e7f6be52362e98557f named entity 'PEPTIDE' named entity 'ACE2' named entity 'EMERGING INFECTIOUS DISEASE' named entity 'SP-4' named entity 'REPORT' named entity 'S PROTEIN' named entity 'DISRUPT' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'INTERACTION' named entity 'CELLULAR' named entity 'ENZYME-LINKED IMMUNOSORBENT ASSAY' named entity 'DOMAIN' named entity 'ACTIVITIES' named entity 'CONCLUSION' named entity 'CAUSED BY' named entity 'INFECTIVITY' named entity 'AGENT' named entity 'PROTEIN ' named entity 'SPIKE' named entity 'VALUES' named entity 'PEPTIDES' named entity 'RETROVIRUS' named entity 'MAY BE' named entity 'INHIBITORY' named entity 'S-PROTEIN' named entity 'SUGGEST' named entity '679' named entity 'NOVEL' named entity 'SARS-COV' named entity 'DESIGN' named entity 'PROTEIN ' named entity 'INTERACTION' named entity 'NMOL' named entity 'BINDING' named entity 'OUR' named entity 'SMALL' named entity 'SCANNING' named entity 'TREATMENT' named entity 'CELLS' named entity '660' named entity 'DERIVED' named entity 'SPIKE PROTEIN' named entity 'PEPTIDES' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity 'INHIBITORY' named entity 'SARS-CoV' named entity 'retrovirus' named entity 'biotinylated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software